OVIT (OncoVista Innovative Therapies) Cash-to-Debt: 0.13 (As of Sep. 2015)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is OncoVista Innovative Therapies Cash-to-Debt?

OncoVista Innovative Therapies OVIT Cash-to-Debt is 0.13 as of Sep. 2015.

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. OncoVista Innovative Therapies's cash to debt ratio for the quarter that ended in Sep. 2015 was 0.13.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, OncoVista Innovative Therapies couldn't pay off its debt using the cash in hand for the quarter that ended in Sep. 2015.

The historical rank and industry rank for OncoVista Innovative Therapies's Cash-to-Debt or its related term are showing as below:

OVIT's Cash-to-Debt is not ranked *
in the Biotechnology industry.
Industry Median: 6.78
* Ranked among companies with meaningful Cash-to-Debt only.

OncoVista Innovative Therapies  (OTCPK:OVIT) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

OncoVista Innovative Therapies Cash-to-Debt Related Terms

OncoVista Innovative Therapies Cash-to-Debt Historical Data

* Premium members only.

The historical data trend for OncoVista Innovative Therapies's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

OncoVista Innovative Therapies Cash-to-Debt Chart

OncoVista Innovative Therapies Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.47 12.65 No Debt No Debt 0.06

OncoVista Innovative Therapies Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.37 0.06 0.17 0.07 0.13

OVIT vs RSPI, HSTC, CAPS: Cash-to-Debt Comparison

For the Biotechnology subindustry, OncoVista Innovative Therapies's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OncoVista Innovative Therapies Cash-to-Debt vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoVista Innovative Therapies's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where OncoVista Innovative Therapies's Cash-to-Debt falls into.


OncoVista Innovative Therapies Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

OncoVista Innovative Therapies's Cash to Debt Ratio for the fiscal year that ended in Dec. 2014 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=0.013 / (0.208 + 0)
=0.06

OncoVista Innovative Therapies's Cash to Debt Ratio for the quarter that ended in Sep. 2015 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=0.061 / (0.479 + 0)
=0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash-to-Debt →
What does a Cash-to-Debt of 0.13 mean?
OncoVista Innovative Therapies (OVIT) has a Cash-to-Debt of 0.13 as of Sep. 2015.
Is OncoVista Innovative Therapies' Cash-to-Debt too high?
OncoVista Innovative Therapies' current Cash-to-Debt is 0.13. The Biotechnology industry median Cash-to-Debt is 6.78. OncoVista Innovative Therapies' value of 0.13 is 98.1% below this industry median.
How does OncoVista Innovative Therapies' Cash-to-Debt compare to RSPI and HSTC?
OncoVista Innovative Therapies' Cash-to-Debt of 0.13 can be compared against companies in the Biotechnology industry. The industry median Cash-to-Debt is 6.78. OncoVista Innovative Therapies' value of 0.13 is 98.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.78, based on 1,371 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OncoVista Innovative Therapies's current Cash-to-Debt of 0.13 is 98.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OncoVista Innovative Therapies's current Cash-to-Debt is 0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoVista Innovative Therapies stock overvalued right now?
OncoVista Innovative Therapies (OVIT) has a current Cash-to-Debt of 0.13. The current Cash-to-Debt is 0.13 and 98.1% below the Biotechnology industry median of 6.78. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For OncoVista Innovative Therapies (OVIT), the current Cash-to-Debt is 0.13 as of Sep. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OncoVista Innovative Therapies Business Description

Address 14785 Omicron Drive, Suite 104, San Antonio, TX, USA, 78245
OncoVista Innovative Therapies Inc is a biopharmaceutical company. It is engaged in developing anticancer therapies by utilizing tumor-associated biomarkers.